Cancer markers (also called tumor markers) are substances produced by cancer cells, or by your body in response to cancer, that show up in blood, urine, or tissue samples. Most are proteins found at higher-than-normal levels when certain cancers are present. Doctors use them to help diagnose cancer, guide treatment decisions, and track whether a cancer is responding to therapy or coming back after treatment.
How Cancer Markers Work
The basic idea is straightforward: cancer cells often release specific proteins or other molecules into the bloodstream that healthy cells either don’t produce or produce in much smaller amounts. By measuring the level of these substances, doctors get a window into what’s happening inside the body. A rising level over time can signal that a tumor is growing, while a dropping level often means treatment is working.
Beyond proteins, newer types of cancer markers include genetic mutations found in tumors and tiny fragments of tumor DNA that break off and circulate in the blood. These genomic markers can reveal not just whether cancer is present, but how aggressive it is and which treatments it’s likely to respond to.
Common Cancer Markers and What They Track
Each marker is associated with one or a few specific cancer types. Here are the ones used most often in clinical practice:
- PSA (prostate-specific antigen): Linked to prostate cancer. Used for diagnosis, monitoring treatment, and detecting recurrence. It’s the only marker routinely used in a screening context for otherwise healthy people.
- CA-125: Primarily associated with ovarian cancer. Helps assess treatment response and check for recurrence.
- CEA (carcinoembryonic antigen): Used mainly for colorectal cancer to evaluate how well treatment is working and to catch recurrence early.
- AFP (alpha-fetoprotein): Connected to liver cancer, ovarian cancer, and germ cell tumors. Helps with diagnosis, staging, and monitoring.
- CA 19-9: Associated with pancreatic, gallbladder, bile duct, and stomach cancers. Primarily used to gauge treatment effectiveness.
- CA 15-3 / CA 27.29: Used for breast cancer to assess whether treatment is working or the cancer has returned.
- HER2: Found in breast, lung, stomach, and several other cancers. Plays a key role in determining which targeted therapies will be effective.
- KRAS gene mutation: Relevant to colorectal and non-small cell lung cancers. Guides treatment selection by indicating whether certain drugs will or won’t work.
- Calcitonin: Used for medullary thyroid cancer to aid diagnosis and track recurrence.
- Thyroglobulin: Used for thyroid cancer to check treatment response and monitor for recurrence.
Four Ways Doctors Use Them
Screening
Screening means testing people who feel healthy and have no symptoms. Despite the appeal of catching cancer early through a simple blood test, most markers aren’t accurate enough for this. Too many non-cancerous conditions can raise levels, leading to false alarms. PSA is the notable exception. Current U.S. guidelines recommend that men aged 55 to 69 discuss PSA-based prostate cancer screening with their doctor and make an individual decision about whether to test. For men 70 and older, routine PSA screening is not recommended.
Helping Confirm a Diagnosis
Cancer markers alone rarely confirm a diagnosis. They lack the precision to do that job on their own. But when combined with imaging, biopsies, and other tests, they help doctors distinguish between cancerous and non-cancerous conditions. In someone already suspected of having cancer, an elevated marker strengthens the case and helps narrow down the type.
Staging and Predicting Outcomes
In some cancers, marker levels reflect how much tumor is in the body, making them useful for staging. For testicular germ cell tumors, for instance, levels of AFP, beta-hCG, and LDH are built directly into the staging system. Higher levels at diagnosis generally point to more advanced disease and help doctors estimate how aggressive treatment needs to be.
There’s a useful distinction here between two types of markers. Prognostic markers indicate how a cancer is likely to behave regardless of treatment, essentially predicting the natural course of the disease. Predictive markers, on the other hand, indicate whether a specific treatment is likely to work. HER2 is a classic predictive marker: if your breast cancer is HER2-positive, targeted therapies exist that dramatically improve outcomes. KRAS mutations serve a similar role in colorectal cancer, telling doctors which treatments to use and which to avoid.
Monitoring Treatment and Catching Recurrence
This is the most common use of cancer markers in everyday oncology. Doctors track marker levels over time during and after treatment. The trend matters more than any single number. A steadily falling level during chemotherapy is a good sign. A rising level after treatment ends can signal recurrence months before a scan would pick it up, a concept sometimes called “biochemical recurrence.” This early warning gives doctors a head start on adjusting the treatment plan.
Why Markers Can Be Misleading
No cancer marker is perfectly reliable. The core problem is that many of these proteins are also produced during non-cancerous conditions, which can trigger a false positive and unnecessary worry. CA-125 is a well-known example. It rises with endometriosis, liver disease, pelvic inflammatory disease, uterine fibroids, menstruation, and pregnancy. That’s why it isn’t used to screen healthy women for ovarian cancer. An elevated CA-125 in someone without symptoms is far more likely to reflect one of these benign conditions than cancer.
False negatives are also possible. Some cancers don’t produce detectable levels of any known marker, and some people with early-stage cancer have perfectly normal marker levels. This is why doctors never rely on a single marker test to rule cancer in or out. Markers are one piece of a larger diagnostic puzzle.
What the Test Is Actually Like
Most cancer marker tests are simple blood draws. A needle goes into a vein in your arm, a small sample is collected, and you’re done in a few minutes. Some markers are measured through urine samples instead. In both cases, you typically don’t need to fast or do any special preparation beforehand.
When doctors need to look for markers directly in tumor tissue (like HER2 or KRAS mutations), that requires a biopsy, where a small piece of the tumor is removed and analyzed in a lab. The type of biopsy depends on where the tumor is located, and your doctor may ask you to fast for several hours before the procedure.
Liquid Biopsies and Multi-Cancer Blood Tests
A newer approach called liquid biopsy looks for tiny fragments of tumor DNA circulating in the blood. Cancer cells constantly shed bits of their DNA into the bloodstream, and these fragments carry the same mutations found in the tumor itself. By analyzing these fragments, doctors can identify specific mutations, track how a cancer responds to treatment, and detect recurrence, all from a standard blood draw rather than a surgical biopsy.
The most ambitious application of this technology is the multi-cancer early detection (MCED) test, a single blood test designed to screen for many cancer types at once. One large study found that a leading MCED test could detect cancer across 21 different types with 98.5% specificity (meaning very few false positives) and 50.9% sensitivity (meaning it catches about half of cancers present). Those sensitivity numbers may sound modest, but the impact on catching cancer earlier is significant.
A 10-year simulation study modeled what would happen if annual MCED testing were added to standard screening. The results showed a 45% decrease in cancers diagnosed at stage IV, when they’re hardest to treat. Stage I diagnoses increased by 10%, and stage II diagnoses rose by 20%. The effect was especially pronounced for lung cancer, colorectal cancer, and pancreatic cancer, three types that are notoriously difficult to catch early with existing tools. Cervical cancer saw the largest relative reduction in late-stage diagnosis at 83%, followed by liver cancer at 74%.
Testing frequency matters. Annual screening produced that 45% reduction in stage IV diagnoses, but testing every two years dropped the benefit to 28%, and every three years to 22%. Consistency of follow-through also plays a role: if only half of eligible people actually complete their tests, the stage IV reduction falls to around 23%.